(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.02%
@ $11.17
Utstedt: 14 feb 2024 @ 21:35
Avkastning: 92.03%
Forrige signal: feb 14 - 20:36
Forrige signal:
Avkastning: 1.92 %
Live Chart Being Loaded With Signals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors...
Stats | |
---|---|
Dagens volum | 467 521 |
Gjennomsnittsvolum | 2.08M |
Markedsverdi | 1.82B |
EPS | $-0.390 ( 2024-03-21 ) |
Neste inntjeningsdato | ( $-0.370 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.79 |
ATR14 | $0.00600 (0.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Leamon Christopher P | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Leamon Christopher P | Buy | 63 700 | Restricted Stock Units |
2023-08-31 | Leamon Christopher P | Buy | 11 957 | Common Stock |
2024-01-04 | Crowley John J | Buy | 106 100 | Stock Option (Right to Buy) |
2024-01-04 | Crowley John J | Buy | 63 700 | Restricted Stock Units |
INSIDER POWER |
---|
99.99 |
Last 91 transactions |
Buy: 6 470 725 | Sell: 164 236 |
Volum Korrelasjon
Fusion Pharmaceuticals Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
QADB | 0.977 |
CMPI | 0.965 |
ALBO | 0.952 |
JNCE | 0.945 |
EBACU | 0.945 |
TZPS | 0.932 |
MCAA | 0.931 |
DXPE | 0.927 |
ARTEU | 0.926 |
IVCB | 0.924 |
10 Mest negative korrelasjoner | |
---|---|
RGF | -0.951 |
IMRX | -0.943 |
ORPH | -0.942 |
PRTS | -0.939 |
ATAK | -0.937 |
NDLS | -0.934 |
MTEM | -0.934 |
RGC | -0.932 |
RMGC | -0.928 |
WKSP | -0.927 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Fusion Pharmaceuticals Korrelasjon - Valuta/Råvare
Fusion Pharmaceuticals Økonomi
Annual | 2023 |
Omsetning: | $2.07M |
Bruttogevinst: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2023 |
Omsetning: | $2.07M |
Bruttogevinst: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2022 |
Omsetning: | $1.46M |
Bruttogevinst: | $-57.43M (-3 931.14 %) |
EPS: | $-2.00 |
FY | 2021 |
Omsetning: | $1.44M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.884 |
Financial Reports:
No articles found.
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.